Episodes

  • Second-Generation Retinal Care: Finding Your Footing Among Shifting Practice Paradigms - Part 3: Dosing for Durability Without Compromising Outcomes

    Second-Generation Retinal Care: Finding Your Footing Among Shifting Practice Paradigms - Part 3: Dosing for Durability Without Compromising Outcomes
    Oct 27 2026

    Please CLICK HERE, or paste the following URL into your browser, (https://activities.paradigmmc.com/14743P) to view the full CME activity and claim credit for your participation.

    • (00:00) - Introduction
    • (06:20) - Dosing Intervals in Treatment-Naïve Patients
    • (09:18) - Dosing Intervals in Previously Treated Patients
    • (16:10) - Defining “Disease Control”
    • (20:51) - Personalized Treatment Intervals and Home OCT
    • (27:46) - Summary

    Same diagnosis, multiple treatment options, vastly different responses. In the era of second-generation therapy, which treatment plans best minimize injection burden while preserving vision?

    In this third and final episode, Dr Goldberg and Dr Weng address the ins and outs of dosing second-generation therapy, including the loading phase and how to individualize injection intervals.

    TRANSCRIPT
    Show More Show Less
    29 mins
  • Second-Generation Retinal Care: Finding Your Footing Among Shifting Practice Paradigms - Part 2: Progress in Biomarker-Based Care

    Second-Generation Retinal Care: Finding Your Footing Among Shifting Practice Paradigms - Part 2: Progress in Biomarker-Based Care
    Oct 27 2026

    Please CLICK HERE, or paste the following URL into your browser, (https://activities.paradigmmc.com/14742P) to view the full CME activity and claim credit for your participation.

    • (00:00) - Introduction
    • (06:23) - Dual Inhibition in Neovascular Retinal Disease
    • (09:37) - Imaging Biomarkers of nAMD
    • (17:50) - Imaging Biomarkers of DME
    • (25:27) - Imaging Tools
    • (27:20) - Summary

    Same diagnosis, multiple treatment options, vastly different responses. In the era of second-generation therapy, which treatment plans best minimize injection burden while preserving vision?

    In part 2 of this 3-part podcast series, Dr Weng and Dr Goldberg dive deeper into imaging. What findings help you choose one therapy over another now that second-generation options are available?

    TRANSCRIPT
    Show More Show Less
    30 mins
  • Second-Generation Retinal Care: Finding Your Footing Among Shifting Practice Paradigms - Part 1: Who’s the Right Patient?

    Second-Generation Retinal Care: Finding Your Footing Among Shifting Practice Paradigms - Part 1: Who’s the Right Patient?
    Oct 27 2026

    Please CLICK HERE, or paste the following URL into your browser, (https://activities.paradigmmc.com/14741P) to view the full CME activity and claim credit for your participation.

    • (00:00) - Introduction
    • (01:40) - Second-Generation Therapy in Treatment-Naïve Patients
    • (10:17) - Treatment Durability in the Real World
    • (20:07) - DRCR.net Protocol AO
    • (21:59) - Considering a Therapy Switch
    • (28:12) - Summary

    Same diagnosis, multiple treatment options, vastly different responses. In the era of second-generation therapy, which treatment plans best minimize injection burden while preserving vision?

    In part 1 of this 3-part podcast series, Dr Goldberg and Dr Weng get to the crux of whom do we start on, and whom do we switch to, second-generation therapy. What flips the switch?

    TRANSCRIPT
    Show More Show Less
    30 mins
  • Incorporating Updates in Advanced Thyroid Cancers: The Role of Targeted Therapies for DTC, ATC, and MTC

    Incorporating Updates in Advanced Thyroid Cancers: The Role of Targeted Therapies for DTC, ATC, and MTC
    Sep 17 2026

    This companion podcast has been adapted from the full CME activity. Please CLICK HERE or paste the following URL into your browser, (https://activities.paradigmmc.com/1444) to participate in the full CME activity (which includes the assessments, slides, interactive questions, and the evaluation) and claim credit for your participation.

    • (00:00) - Intro
    • (01:05) - Introduction to Advanced Thyroid Cancers
    • (10:36) - Understanding Advanced DTC
    • (21:13) - Overview of ATC
    • (33:03) - Understanding MTC
    • (44:15) - Conclusions

    Advanced thyroid cancers pose unique diagnostic and treatment challenges, particularly because many clinicians encounter few cases in practice. This 60-minute CME lecture will provide a concise update on the management of differentiated, anaplastic, and medullary thyroid cancers (DTC, ATC, MTC), with a focus on emerging evidence, guideline-directed care, and personalized treatment strategies. Our faculty will review the role of molecular testing and biomarkers in treatment selection, discuss current systemic therapies, and address practical approaches to monitoring and managing treatment-related adverse events (AEs) to optimize patient outcomes.

    TRANSCRIPT
    Show More Show Less
    47 mins
  • New and Emerging Mechanisms in the Treatment of Systemic Lupus Erythematosus

    New and Emerging Mechanisms in the Treatment of Systemic Lupus Erythematosus
    Aug 3 2026

    Please CLICK HERE, or paste the following URL into your browser, (https://activities.paradigmmc.com/1460P) to view the full CME activity and claim credit for your participation.

    • (00:00) - Welcome and Introduction
    • (05:54) - B Cell Targets in Lupus
    • (07:58) - Targeting BAFF
    • (11:55) - Dual Targeting APRIL and BAFF
    • (15:11) - B-Cell Depletion Via the BAFF Receptor
    • (17:57) - Type II Anti-CD20
    • (28:20) - Bispecific T-Cell Engagers
    • (32:51) - CAR-T Cells in SLE

    B cells play a major role in the pathology of systemic lupus erythematosus (SLE), and several treatments have focused on blocking activation or depleting large subsets of B cells based on surface markers. From anti-CD20 antibodies to chimeric antigen receptor (CAR) T cells, varying depths of B-cell depletion have demonstrated a range of efficacies and durations of response. In addition, these treatments vary in administration, preparation, ease of use, and potential adverse effects. The faculty will provide an engaging discussion on the categories of emerging B-cell therapies and their potential use in SLE.
    Show More Show Less
    39 mins